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Abstract 
Several studies have suggested that the neuropeptide oxytocin may enhance aspects of social communication in autism. 
Little is known, however, about its effects on non-social manifestations, such as restricted interests and repetitive 
behaviors. In the Empathizing-Systemizing Theory of autism, social deficits are described along the continuum of 
empathizing ability, whereas non-social aspects are characterized in terms of an increased preference for patterned or 
rule-based systems, called “systemizing.” We therefore developed an automated eye-tracking task to test whether 
children and adolescents with autism spectrum disorder (ASD) compared to matched controls display a visual 
preference for more highly organized and structured (“systemized”) real-life images. Then, as part of a randomized, 
double-blinded, placebo-controlled crossover study, we examined the effect of intranasal oxytocin on systemizing 
preferences in 16 male children with ASD, compared with 16 matched controls. Participants viewed 14 slides, each 
containing 4 related pictures (e.g. of people, animals, scenes, or objects) that differed primarily on the degree of 
systemizing. Visual systemizing preference was defined in terms of the fixation time and count for each image. Unlike 
control subjects who showed no gaze preference, individuals with ASD preferred to fixate on more highly systemized 
pictures. Intranasal oxytocin eliminated this preference in ASD participants, who now showed a similar response to 
control subjects on placebo. In contrast, control participants increased their visual preference for more systemized 
images after receiving oxytocin vs. placebo. These results suggest that, in addition to its effects on social 
communication, oxytocin may play a role in some of the non-social manifestations of autism.  
Keywords: Autism spectrum disorder, oxytocin, systemizing, restricted interests, eye tracking. 
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Visual Systemizing Preference in Children with Autism: A Randomized Controlled Trial of Intranasal Oxytocin 
 
Almost seventy-five years ago, Leo Kanner first described a group of atypically developing children with two 
distinct symptom profiles: "autistic aloneness" and an "obsessive insistence on the preservation of sameness" (Kanner, 
1943). Since that time, various diagnostic algorithms have characterized what has become known as Autism Spectrum 
Disorder (ASD), the most recent being the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (APA, 
2013; Baker, 2013). Paralleling Kanner’s original description, the DSM-5 describes both social and non-social 
behavioral domains: 1) deficits in social communication, and 2) restricted, repetitive patterns of behavior, interests or 
activities. Although several theoretical frameworks such as Theory of Mind and Social Motivation Theory (S. Baron-
Cohen, Leslie, & Frith, 1985; Chevallier, Kohls, Troiani, Brodkin, & Schultz, 2012) have been proposed to explain the 
social deficits seen in ASD, few have adequately accounted for the non-social behavioral differences, or captured the bi-
dimensional nature of autism.  
In 2009, Baron-Cohen formulated the Empathizing-Systemizing Theory of autism (S. Baron-Cohen, 2009), 
which integrated both social and non-social aspects in terms of deficits in empathy (understanding and feeling the 
mental states of others, or “empathizing”) and the drive to analyze or construct rule-based systems or patterns (termed 
“systemizing”). In individuals with ASD, empathizing traits are inversely correlated with systemizing preferences (S. 
Baron-Cohen, Richler, Bisarya, Gurunathan, & Wheelwright, 2003; Grove, Baillie, Allison, Baron-Cohen, & Hoekstra, 
2013); in other words, individuals who score highest for systemizing traits (such as being more detail oriented, tending 
to follow a structured routine, and being rigidly governed by rules), are more likely to score lower in the empathizing 
domain (such as valuing relationships, judging the feelings of others, expressing emotions, etc.). Males tend to score 
higher in the systemizing domain, while females generally tend to score higher in the empathizing domain, which may 
also help to explain some of the gender differences in ASD (Simon Baron-Cohen, Knickmeyer, & Belmonte, 2005). 
Consistent with the concept of systemizing, children with ASD appear to have a preference for predictable, 
repetitive patterns of sensory stimulation, as observed in the tendency to line up toys, categorize objects, and fixate on 
familiar patterns and interests. One study using automated eye tracking showed that a sample of young children with 
ASD had a visual preference for videos of computer generated geometric patterns over social stimuli (i.e. children 
moving rhythmically) (Pierce, Conant, Hazin, Stoner, & Desmond, 2011). In the current study, our first aim was to test 
whether children with ASD prefer to view more organized or structured real-life images with predictable, repetitive 
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patterns. Using a novel eye-tracking paradigm viewing a range of systemized images, we obtained a quantitative 
assessment of interest or motivation based on gaze preference, independent of verbal or cognitive ability (Boraston & 
Blakemore, 2007).   
In searching for clues regarding the etiology of ASD, few studies have successfully linked both social and non-
social aspects of the condition within a single neurobiological framework (Strathearn, 2009). Over recent years, an 
increasing number of studies, both human and non-human mammalian, have suggested that the brain’s oxytocinergic 
system may play a role in the development or manifestation of ASD (Bartz & Hollander, 2008; Domes, Heinrichs, et al., 
2013; Domes, Kumbier, Heinrichs, & Herpertz, 2013; Gordon et al., 2013; Modi & Young, 2012; Sala et al., 2011; 
Stavropoulos & Carver, 2013). Oxytocin is a neuromodulatory peptide hormone synthesized in the paraventricular and 
supraoptic nuclei of the hypothalamus, whose function has been linked with social bonding and attachment (Feldman, 
2012; Insel, 2010; Kim, Fonagy, Koos, Dorsett, & Strathearn, 2014; Strathearn, Fonagy, Amico, & Montague, 2009; 
Strathearn, Iyengar, Fonagy, & Kim, 2012). Recently, more nuanced effects have been described in the areas of social 
salience and motivation, reward sensitivity, and stress reactivity (Crespi, 2016). Generally, oxytocin appears to diminish 
stress responses while increasing the salience and reward value of social cues.  
In studies involving healthy individuals, intranasally administered oxytocin enhances feelings of empathy 
(Hurlemann et al., 2010) and many other characteristics associated with the empathizing trait, such as mentalizing 
(Domes, Heinrichs, Michel, Berger, & Herpertz, 2007), trust (Kosfeld, Heinrichs, Zak, Fischbacher, & Fehr, 2005), 
emotion recognition (Domes et al., 2010) and eye gaze (Guastella, Mitchell, & Dadds, 2008). These effects of oxytocin 
appear to be mediated via functional changes in specific brain regions such as the amygdala and the nucleus accumbens, 
which are involved in emotion processing and social motivation (Gordon et al., 2016). However, the biological 
mechanisms by which oxytocin may affect systemizing have not been well studied. One group showed the effect of 
oxytocin on amygdala functioning to be moderated by individual levels of “systemizing” (Hirosawa et al., 2012), 
suggesting that oxytocin may indirectly influence systemizing via its effect on empathizing in the amygdala. As 
empathizing and systemizing are strongly negatively correlated (Grove et al., 2013), increasing social attunement may 
diminish the preference for structure and predictability. 
Earlier studies in autism using a single dose of intranasal oxytocin revealed promising effects, such as 
increased emotion recognition when observing the eye region of human faces (Andari et al., 2010; Domes, Kumbier, et 
al., 2013; Guastella et al., 2010), enhanced brain amygdala response to social cues (Domes, Heinrichs, et al., 2013; 
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Domes, Kumbier, et al., 2013), and increased reciprocated social interaction (Andari et al., 2010). Repeated dose studies 
have been few in number and have shown mixed results. Initial studies showed no significant effects on social 
interaction skills, repetitive behaviors, or clinical outcomes (Dadds et al., 2014; Guastella et al., 2015), but more recent 
trials have demonstrated modest effects with regard to social behavior and clinical ratings (Watanabe et al., 2015; 
Yatawara, Einfeld, Hickie, Davenport, & Guastella, 2015).  Few studies have examined the effect of oxytocin on non-
social behaviors such as systemizing preference in autism. In one preliminary study, adults with ASD who were given a 
peripheral infusion of oxytocin showed reduced repetitive behavior (Hollander et al., 2003). Another pilot study testing 
the chronic administration of intranasal oxytocin in ASD adults showed a marginally significant decrease in lower-
ordered repetitive behaviors such as stereotyped movements, but no difference in higher-order behaviors such as 
compulsions or insistence on sameness (Anagnostou et al., 2012). Our second aim was therefore to test whether acutely 
administered intranasal oxytocin would diminish visual systemizing preferences in ASD. 
In summary, we sought to 1) test whether children and adolescents with ASD preferentially view more highly 
organized/structured images, using a novel preferential looking eye tracking paradigm, and 2) examine the effect of 
intranasal oxytocin on these visual systemizing preferences. We hypothesized that participants with ASD would show a 
visual preference for more highly systemized real-life photographs, compared with matched-control participants, and 
that this preference would be reduced after administration of intranasal oxytocin.  
Methods 
Participants 
Twenty males with ASD (mean age 12.5 years) were recruited through the Autism Treatment Network (ATN) 
and Simons Simplex Collection (SSC) at Baylor College of Medicine/Texas Children’s Hospital’s Autism Center.  All 
participants with ASD were assessed by a trained clinician who ensured that they met clinical criteria for Autistic 
Disorder or Asperger’s Disorder according to DSM-IV criteria. The Autism Diagnostic Interview-Revised (ADI-R) and 
the Autism Diagnostic Observation Schedule (ADOS) (Lord, Rutter, DiLavore, & Risi, 1999) were used to confirm that 
each participant met formal, standardized criteria for a diagnosis of ASD. All of the SSC children except one received 
an ADOS Module 3, indicating that they were verbally fluent and spoke in complete, complex sentences. The remaining 
child received an ADOS Module 2, indicating at least phrase speech and/or simple sentences. These children also 
received the Differential Abilities Scales-II (DAS-II), which revealed a mean full-scale IQ of 92.3±12.6, verbal IQ of 
92.5±18.4, and non-verbal IQ 97.0±12.5. All participants were aged between 8 and 19 years; were English speaking; 
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and were not intellectually impaired, as established by developmentally appropriate psychometric testing. Exclusion 
criteria included uncorrected visual impairment; neurological disease, such as stroke, brain tumor, or seizure disorder; 
or a history of meningitis or encephalitis.  
The participants with ASD were matched by age and race to a group of typically developing males (mean age 
13.2 years), who were recruited from a community database at the Children’s Nutrition Research Center, Baylor 
College of Medicine. Prior to enrollment, control participants were screened by phone to rule out possible learning or 
behavior problems (i.e. a diagnosed learning disability or need for special education services, as per parent report). 
Parents subsequently completed the Strengths and Difficulties Questionnaire (SDQ) (Goodman, 1997), which 
confirmed that all control participants scored at “low risk” for emotional, behavioral, or hyperactivity/concentration 
problems. To screen for autistic traits, parents completed the Social Communications Questionnaire (SCQ) (Rutter, 
2003), with all control participants scoring well below the study-imposed, stringent cut-off score of 10 (mean score 2.9, 
range 0-7). Parents of participants from both groups completed the Vineland Adaptive Behaviors Scales (2nd edition) 
(Sparrow, Cicchetti, & Balla, 2005) and, as expected, participants with ASD scored significantly lower on overall 
adaptive functioning (t = 5.2, p < 0.001), and on each of the individual subscales: social (t = 7.8, p < 0.001), 
communication (t = 4.4, p < 0.001), and daily living (t = 3.3, p < 0.005) (Table 1).  
Two participants with ASD did not return for their second visit, and two others were excluded from further 
analyses; one had been started on a psychotropic medication between visits, and the other had poor-quality eye-tracking 
data. Thus, a total of 16 participants with ASD and 16 corresponding control participants were included in the final 
analysis. Of those with ASD, 11 (69%) were taking psychotropic medications at the time of the study visits, including 
stimulant medications for Attention Deficit Hyperactivity Disorder (n = 6), medication for depression or anxiety (n = 4), 
and mood stabilizers (n = 4). None of the control participants were on psychotropic medications or had comorbid 
conditions, as assessed using the SDQ. Additional participant characteristics are described in Table 1.  
The Institutional Review Board at Baylor College of Medicine approved the research protocol, and the 
participants’ parents provided written informed consent and certified child assent. The Food and Drug Administration 
(FDA) approved the use of oxytocin in this study as part of an Investigational New Drug (IND) application. 
Apparatus and Stimuli 
Eye tracker. Real-time eye movements and visual fixations were recorded using the Tobii T120 automated 
eye tracker (Tobii Technology, Sweden). The eye tracker consists of two infrared light sources and a camera (frame rate 
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640 x 480 @ 30 frames per second) integrated into a 17-inch computer monitor, on which the visual stimuli were 
displayed. Using corneal reflection techniques to track both bright and dark pupils, x and y coordinates of eye gaze 
position were recorded at a rate of 60 Hz, with an estimated accuracy between 0.4° and 0.6° (i.e. difference between 
measured and actual gaze direction) (Tobii, 2011). Spatial resolution was estimated to be 0.3° and drift due to change in 
lighting 0.1°.  
Visual stimuli: The Systemizing Picture Task. In order to test gaze preferences in ASD, we developed the 
Systemizing Picture Task (SPT), using real-life images of people, animals, scenes, and objects (Figure 1). Each slide 
consisted of 4 related images, positioned in each quadrant of the slide, that were equivalent in terms of social relevance 
but which varied systematically in terms of organization or structure (“systemizing”). 
Upon initial selection of 22 slides, we sampled 8 individuals to rate each picture on level of systemizing. 
Systemizing was defined for participants as the level of organization indicated by the picture. Across the participants, 
this initial rating yielded a median concordance (Kendall’s W) of .911. We selected 70% agreement on the rank 
ordering as the minimum criteria (W=.84). On this basis, 7 slides were eliminated. We eliminated an additional slide 
which appeared to distract participants. The remaining 14 slides were re-rated on systemizing by a further group of 39 
individuals, which yielded a median Kendall’s W coefficient of .871. These final systemizing ratings were used to 
assign rank orders to the four pictures within each slide. 
 Each picture in this final set of slides was also rated for valence (9-point scale), humanness (5-point scale), 
aliveness (5-point scale), and movement (5-point scale). These ratings yielded high reliability as indicated by 
Cronbach’s alphas of .858, .961, .837, and .828, respectively. The averaged humanness, aliveness, and movement scores 
were later entered into statistical models to control for potential confounding effects. 
 Four different versions of the experiment were created, varying the positions of the four pictures within each 
slide, in order to minimize possible gaze bias based on picture location. The different versions were consistent between 
matched subjects. 
Procedure 
Oxytocin administration. As part of a randomized, double-blinded crossover study, participants were 
randomly assigned one nasal solution on Visit 1 and the alternate solution on Visit 2. The intranasal oxytocin 
(Syntocinon Spray, Novartis, Switzerland) was purchased from a Swiss pharmacy, and a local compounding pharmacy 
prepared the placebo sprays using identical base ingredients (for 5 ml of placebo solution: 12.5 mg chlorobutanol 
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hemihydrate, 2 mg methyl-4-hydroxybenzoate, 1 mg propyl-4-hydroxybenzoate, 14 mg citric acid monohydrate, 125 
mg glycerine 85%, and 4.85 g purified water; for active drug: 24 IU oxytocin per ml). The oxytocin solution and the 
placebo (base alone) were stored in identical glass metered pump spray bottles (0.1 ml per spray) and labeled to ensure 
that both participants and experimenters were blind to the drug treatment. 
Trained research assistants administered either the oxytocin or the placebo spray intranasally. Children 16 
years and older received the usual adult dose of 24 IU oxytocin (10 puffs alternating between nostrils with the head in 
the upright position, each spray containing 2.4 IU), while doses for younger children were titrated downward, similar to 
Guastella et al. (2010). Those aged 12-15 years received 7 puffs (16.8 IU), while children aged 8-11 years received 5 
puffs (12 IU total). 
After oxytocin administration, participants rested while watching an animated film or reading quietly. A 
similar activity was provided during the second visit, to standardize the environment across visits. Approximately 30 
minutes after oxytocin administration, the participants commenced the eye-tracking experiment. 
Eye-tracking experiment. After performing a 9-point eye-tracking calibration using the Tobii Studio software 
(Tobii Technology, Sweden), an instruction slide appeared that was read aloud to the participant, followed by a practice 
slide. A crosshair was shown for 1 second between each slide, and participants were instructed to gaze directly at the 
crosshair when present. During the experiment, the monitor displayed each SPT slide for 12 seconds (except for 3 
participants who viewed the slides for 8 seconds each; sensitivity analysis revealed no difference in the pattern of 
findings and therefore these 3 participants were included in all of the analyses). After the entire eye-tracking computer 
task was completed, participants received compensation, were presented with a certificate of completion, and scheduled 
to return in approximately 1-2 weeks’ time for the corresponding study visit.  
Data Analysis 
Eye-gaze data were extracted from the four pictures/regions of interest (ROI) on each slide, which depicted the 
theme at four different levels of organization or structure (i.e., least systemized, less systemized, more systemized, most 
systemized) (Figure 1). We exported and analyzed, as our outcome measures: a) fixation time (total duration of fixation) 
and b) fixation count (total number of fixations) in each ROI. Fixation was defined as an eye gaze that remained 
stationary (within 1° radius, or approximately 35 pixels) for a minimum of 80 msec. Proportion variables were 
calculated by dividing the fixation values (time or count) recorded for each quadrant by the respective total value 
obtained for the entire slide. As the proportions were not distributed normally, a range of transformations was 
OXYTOCIN AND SYSTEMIZING PREFERENCES IN AUTISM                                                                                9 
 
performed. Intercept-adjusted logarithmic transforms offered the closest approximation to normality. The random-effect 
models controlled for ROI location on the slide and visit order, as we probed for significance of the group x treatment x 
systemizing interaction. Participants’ performance across four levels of systemizing was represented by random effects 
parameters. Three additional variables (participant age, picture “humanness”, and picture “aliveness”) were added to the 
model individually, to test for any confounding influence. Analyses were performed in STATA/SE 13.1 and IBM SPSS 
Statistics (version 21). 
Results 
Means and standard errors of fixation variables are presented in Table 2. Consistent with our hypothesis, the 
ASD group showed a visual preference for more highly systemized images in the standard placebo (PL) condition 
(Figure 2). There was a significant linear trend of increase in the fixation time of ASD participants with increasing 
levels of picture systemizing (ASDPL βsystemizing = 0.0041 ± 0.002 [standard error], z = 2.00, p = 0.045), while no such 
effect was seen in the control group (CTLPL βsystemizing = 0.0006 ± 0.0018, z = 0.32, p = 0.748).  
Oxytocin, however, reversed the overall patterns of fixation observed under placebo, as reflected in a 
significant 3-way interaction (βgroup x treatment x systemizing = -0.0119 ± 0.0039, z = -3.04, p = 0.002) (Figure 3). For the ASD 
group, oxytocin eliminated the tendency to fixate on more highly systemized pictures, as seen in a significant two-way 
interaction (ASD βtreatment x systemizing = -0.0070 ± 0.0030, z = -2.33, p = 0.020) (Figure 3A). In particular, after receiving 
intranasal oxytocin compared with placebo, ASD participants showed significantly less fixation on the “most 
systemized” pictures (ASD βtreatment = -0.0215 ± 0.0104, z = -2.07, p = 0.038). The ASD group showed no persisting 
gaze preference after receiving intranasal oxytocin (OT) (ASDOT βsystemizing = -0.0030 ± 0.0022, z = -1.38, p = 0.169), 
similar to what was seen in the control group under placebo conditions (CTLPL βsystemizing = 0.0006 ± 0.0018, z = 0.32, p 
= 0.748; Figure 3B). 
In contrast, the control group became more likely to fixate on more systemized pictures after oxytocin 
administration (CTLOT βsystemizing = -0.0065 ± 0.0018, z = 3.60, p < 0.001), with a significant 2-way interaction observed 
(CTL βtreatment x systemizing = 0.0054 ± 0.0026, z = 2.13, p = 0.033) (Figure 3B). However, the difference in fixation time 
after oxytocin vs. placebo was not statistically significant for either “most systemized” or “least systemized” pictures 
(CTL βtreatment = 0.0164 ± 0.0104, z = 1.57, p = 0.116; βtreatment = -0.0147 ± 0.0104, z = -1.41, p = 0.158, respectively).  
Overall, oxytocin resulted in a decrease in systemizing preference (βsystemizing) in ASD participants (Figure 3A), 
but an increase in systemizing preference for control participants (Figure 3B), resulting is a highly significant 2-way 
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interaction effect (OT βgroup x systemizing = -0.0087 ± 0.0028, z = -3.07, p = 0.002). Figure 4A illustrates the change in slope 
after oxytocin administration comparing ASD and CTL groups. 
Similar gaze patterns were seen after examining the total number of fixations in each region of interest 
(fixation count) (Table 2), except that the interaction effect between drug treatment and level of systemizing in the 
control group was no longer statistically significant (CTL βtreatment x systemizing = 0.0041 ± 0.0022, z = 1.86, p = 0.063).  
None of the independent ratings of picture “humanness” or “aliveness” were associated with fixation time or 
count, and these variables did not alter any of the significant main or interaction effects. The age variable was also not 
associated with either of the outcome variables and did not significantly alter any of the observed effects.  
Discussion 
This study is the first to examine the effects of intranasal oxytocin, in both ASD and non-ASD groups, on what 
we have termed “visual systemizing preference,” a non-social manifestation of ASD. Firstly, we confirmed that our 
novel eye-tracking task was able to distinguish children/adolescents with ASD from non-ASD controls. Secondly, we 
showed that when intranasal oxytocin was administered to ASD participants, it effectively eliminated the difference 
between ASD and control participants. Surprisingly, however, oxytocin also increased systemizing preference when 
administered to control participants. Understanding how oxytocin affects both social and non-social aspects of ASD, in 
affected and unaffected individuals, may provide clues for understanding its potential role in the etiology and treatment 
of autism. 
Oxytocin in ASD 
There are no currently approved pharmacotherapies available to treat the core social or non-social 
manifestations of ASD. As noted above, early studies provided preliminary evidence for the beneficial effects of single 
dose intranasal oxytocin in adolescents and adults with autism, with regard to both social communication (Andari et al., 
2010; Guastella et al., 2010) and repetitive behavior (Anagnostou et al., 2012; Hollander et al., 2003). Subsequent 
studies of repeated administrations of oxytocin have shown variable effects on behavioral outcomes, ranging from no 
significant effects on social skills or repetitive behavior (Dadds et al., 2014; Guastella et al., 2015), to improved social 
reciprocity and clinical ratings of behavior (Watanabe et al., 2015; Yatawara et al., 2015). Other human studies in non-
clinical populations have shown improvements in a range of responses relevant to autism, including emotional empathy 
(Hurlemann et al., 2010), eye gaze (Guastella et al., 2008), trust (Baumgartner, Heinrichs, Vonlanthen, Fischbacher, & 
Fehr, 2008), and the ability to read the affective state of others (Domes et al., 2007).  
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Despite an abundance of media attention on the promises of oxytocin therapy in conditions such as ASD, 
concerns remain about anomalous effects or even unanticipated adverse effects (Bales & Perkeybile, 2012; Bales et al., 
2012; J. Bartz et al., 2011; De Dreu et al., 2010; Miller, 2013). A number of studies have noted variations in oxytocin 
response depending on individual differences and other contextual factors (Bartz, Zaki, Bolger, & Ochsner, 2011). 
Other work has shown, for example, that plasma oxytocin response to social cues (mothers interacting with their 
infants) varies with adult temperament, being positively associated with sensitivity to moods, emotions and physical 
sensations, but negatively associated with compulsive and task oriented behavior (Strathearn et al., 2012), which parallel 
empathizing and systemizing traits respectively.  
Systemizing and Empathizing in ASD 
Baron-Cohen first hypothesized that autism may result from an extreme tendency to “systemize” or seek out 
regularities or predictable patterns and rules (S. Baron-Cohen, 2009). This preference for patterned over unpatterned 
information may help to explain some of the restricted, repetitive behaviors and interests characteristically observed in 
individuals with ASD. Consistent with this model, our findings, along with those of Pierce et al. (2011), show that 
individuals with ASD display a preference for more patterned or “systemized” visual stimuli.  
According to Baron-Cohen’s theory, hyper-systemizing is also often accompanied by deficits in 
“empathizing,” or the ability to identify and appropriately respond to another person's thoughts and emotions (S. Baron-
Cohen & Wheelwright, 2004), with deficits in social communication characteristically seen in ASD. Individuals with 
ASD tend to score higher than the general population on measures of systemizing but lower on empathizing measures 
(Auyeung et al., 2009; S. Baron-Cohen, 2009).  
Effects of Oxytocin in Non-ASD Participants 
As noted, we also found that oxytocin increased visual systemizing preference in control participants, resulting 
in a gaze preference similar to ASD participants under placebo conditions (Figure 3A & B). Although not predicted, this 
result is consistent with a growing body of literature demonstrating that the effects of oxytocin are significantly 
modulated by individual differences. Oxytocin receptor deficient mice, which display social deficits as well as cognitive 
inflexibility, serve as an animal model for ASD. After intraventricular administration of oxytocin, social deficits 
improve and cognitive inflexibility decreases (Ring, 2011; Sala et al., 2011). However, when the same dose of oxytocin 
is administered to unaffected mice, the opposite effect is observed. While Hollander et al. (2003) reported that 
intravenous oxytocin resulted in a decrease in repetitive behaviors in adults with autism, higher oxytocin levels are 
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associated with an increase in repetitive behavior in adults with obsessive-compulsive disorder (Leckman et al., 1994). 
Although intranasal oxytocin enhances emotion recognition in individuals with ASD (Bartz et al., 2010; Guastella et al., 
2010), one study showed that oxytocin decreases the accuracy of emotion recognition when administered to a normative 
sample (Cardoso, Ellenbogen, & Linnen, 2013).  Oxytocin enhances trust and cooperation in normative populations 
(Declerck, Boone, & Kiyonari, 2010; Kosfeld et al., 2005), but appears to have the opposite effect in individuals with 
borderline personality disorder (J. Bartz et al., 2011). Finally, Groppe et al. (2013) showed that the effect of oxytocin on 
performance in a social reward and punishment task depended on whether the individuals had high or low sociability 
ratings. In the low sociability group, oxytocin increased social reward while avoiding punishment, whereas reduced 
performance was seen in the high sociability group.  
Together, these findings suggest that an optimal range may exist for oxytocin functioning, with its behavioral 
effects dependent on individual differences that may reflect baseline oxytocin levels, oxytocin receptor status, or 
interactions with other neuroendocrine factors. A similar “optimal range” model for autism was proposed by Zoghbi and 
Bear (2012), based on “high” vs. “low” levels of gene expression and effects on synaptic plasticity. In our study, 
intranasal oxytocin appears to move ASD participants toward more typical responses in the Systemizing Picture Task, 
while moving control participants further away (Figure 4). Studies have suggested that individuals with ASD may have 
lower peripheral levels of oxytocin compared to matched-controls (Feldman, Golan, Hirschler-Guttenberg, Ostfeld-
Etzion, & Zagoory-Sharon, 2014; Green et al., 2001; Modahl et al., 1998), and that intranasally administered oxytocin 
increases plasma oxytocin levels (Andari et al., 2010). If peripheral oxytocin levels reflect central oxytocin functioning 
(McGregor, Callaghan, & Hunt, 2008; Strathearn et al., 2009; Valstad et al., 2017), then giving intranasal oxytocin may 
move individuals with ASD from the “low” to the “normal” range of functioning (Figure 4B). Likewise, giving 
oxytocin to neurotypical control participants may move them from the “normal” to the “high” oxytocin range, resulting 
in the observed behavioral differences.  
We hypothesize that a similar, but inverted, pattern may also exist for the effect of oxytocin on social 
responses in ASD, with other studies providing evidence for a non-linear effect on behaviors more closely associated 
with “empathizing” (Bales et al., 2012; Bales et al., 2007; J. Bartz et al., 2011; Cardoso et al., 2013; Sala et al., 2011) 
(Figure 4B). Additional studies, which also collect peripheral measures of oxytocin before and after intranasal 
administration, are needed to explore this question more fully.  
Limitations and Future Directions 
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Several limitations of this study need to be considered. Firstly, having created a novel eye-tracking task to 
examine gaze preference for more organized or structured images, the Systemizing Picture Task has not yet been 
validated against other measures of systemizing. The original Systemizing Quotient (S. Baron-Cohen et al., 2003) and 
Autism Spectrum Quotient (S. Baron-Cohen, Wheelwright, Skinner, Martin, & Clubley, 2001) were not suitable for 
administration in children and adolescents, and a subsequent children’s version which relied solely on parent report 
(Auyeung et al., 2009) was not available at the time that the study commenced. Comparing our task with other validated 
measures of systemizing will help to expand our understanding of its meaning and clinical significance.  
Although we sought to control for variations in picture composition and meaning, such as the “humanness” and 
“aliveness”, other physical aspects of the pictures, such as color, intensity or background features, may have also 
influenced gaze preference. Our desire to use “real-world” images limited our ability to standardize many of these other 
features. Although “age,” when added as a covariate, did not significantly alter study findings, the enrolled groups did 
encompass a broad range of ages, with a relatively small number of participants. Future studies enrolling larger 
numbers, and including female participants, may be able to look more specifically for age and gender response 
differences. An additional limitation includes a lack of systematic information on psychiatric comorbidity. Further 
studies are warranted to investigate possible contributions of psychiatric comorbidity to the findings reported here. 
Additional studies will also need to test whether intranasal oxytocin enhances functioning in real-life 
environments, or influences long-term outcomes in ASD. Only after more intensive studies are conducted evaluating 
outcome will we know whether a potential opportunity exists to combine pharmacological treatment with 
therapeutic/behavioral interventions.  
Conclusion 
Most recent prevalence estimates indicate that up to 1 in 68 children may be affected by ASD (CDC, 2016), 
with affected individuals and families usually requiring intensive and costly therapeutic intervention to optimize long-
term developmental and behavioral outcomes. Understanding the neuroendocrine basis for this condition is an urgent 
imperative. This study provides preliminary evidence for a possible role of oxytocin in the etiology and/or treatment of 
autism by demonstrating its effect on a non-social manifestation of ASD. With oxytocinergic pathways highly sensitive 
to early developmental experience via epigenetic mechanisms (F. A. Champagne, 2008; F. Champagne, Diorio, Sharma, 
& Meaney, 2001; Kumsta, Hummel, Chen, & Heinrichs, 2013), this understanding may provide an even more important 
opportunity for early intervention and/or prevention.  
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Table 1 
Demographic and Behavioral Characteristics of ASD and Control Participants 
 Control ASD 
 
M ± SD 
(n = 16) 
Range 
M ± SD 
(n = 16) 
Range 
 
Participant age on first visit (years)  
 
13.2 ± 3.2 
 
9.2 - 19.6 
 
12.8 ± 3.4 
 
8.2 - 19.0 
Race, N (%) 
    
                White 9 (56.3%) 
 
9 (56.3%) 
 
                Non-White 7 (43.7%) 
 
7 (43.7%) 
 
Hollingshead Socioeconomic Status  49.3 ± 12.0 29.0 - 66.0 42.3 ± 14.5 9.0 - 63.5 
Psychiatric Comorbidity*     
                ADHD 0  6 (37.5%)  
                Anxiety/depression 0  4 (25%)  
                Mood instability 0  4 (25%)  
Reported annual household income, n (%) 
    
                Not reported 3 (18.8%) 
 
2 (12.5%) 
 
                < $65,000 4 (25%) 
 
7 (43.8%) 
 
                $66,000-$100,000 4 (25%) 
 
2 (12.5%) 
 
                > $100,000 5 (31.2%) 
 
5 (31.3%) 
 
Vineland Composite Score 104.3 ± 12.3 
(n = 15) 
84 - 126 74.5 ± 16.3 
(n =10) 
39 - 90 
                Communication 102.9 ± 13.8 
(n = 16) 
82 - 134 75.2 ± 19.0 
(n = 11) 
38 - 101 
                Daily Living 108.0 ± 19.6 
(n = 15) 
78 - 146 81.2 ± 20.7 
(n = 10) 
38 - 109 
                Social        103.1 ± 10.0 
(n = 16) 
87 - 119 67.8 ± 13.6 
(n = 11) 
46 - 87 
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*based on medication prescription 
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Table 2 
Visual Systemizing Preferences Based on Fixation Time and Count, in Control and ASD Groups as a Function of 
Oxytocin and Level of Picture Systemizing 
  Fixation time  Fixation count  
  Placebo Oxytocin  Placebo Oxytocin  
        
Control (n =16)        
        
      Least systemized  0.212 ± 0.008 0.198 ± 0.008  0.215 ± 0.007 0.204 ± 0.007  
      Less systemized  0.214 ± 0.005 0.210 ± 0.005  0.216 ± 0.004 0.213± 0.004  
      More systemized  0.216 ± 0.005 0.222 ± 0.005  0.217 ± 0.004 0.223 ± 0.004  
      Most systemized  0.218 ± 0.008 0.234 ± 0.008  0.219 ± 0.007 0.232 ± 0.007  
        
        
      Wald χ2  32.01  25.10  
       p  0.0004  0.005  
        
        
ASD (n =16)        
        
      Least systemized  0.201 ± 0.008 0.220 ± 0.008  0.203 ± 0.007 0.220 ± 0.007  
      Less systemized  0.209 ± 0.005 0.215 ± 0.005  0.211 ± 0.004 0.216 ± 0.004  
      More systemized  0.217 ± 0.005 0.209 ± 0.005  0.219 ± 0.004 0.212 ± 0.004  
      Most systemized  0.226 ± 0.008 0.204 ± 0.008  0.227 ± 0.007 0.208 ± 0.007  
        
        
      Wald χ2  32.97  35.81  
       p  0.0003  0.0001  
        
 
Note. Duration and frequency values (estimated marginal means ± SE) shown are log-transformed proportion values, 
adjusted for the total duration and number of fixations recorded for each slide. Wald χ2 and p-values are those obtained 
for the best-fitting mixed-effects models for the respective outcome variables, including a subject-level random 
intercept and a random coefficient for level of picture systemizing. df = 10 for all models. 
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Figure Captions 
Figure 1. Systemizing Picture Task. Representative slides displayed on the Tobii eye-tracker, showing four levels of 
picture systemizing. The position of each picture was pseudo-randomized across 4 versions of the task, and the position 
of the most and least systemized pictures varied between slides. The 3 primary factors in the model included ASD vs. 
control group, treatment (oxytocin vs. placebo), and level of picture systemizing. Comparable but not actual images 
used in the task are shown, due to copyright constraints. 
Figure 2. Visual systemizing preferences in ASD versus control groups, in the placebo condition. A. Representative 
heat maps visualizing differences in relative gaze duration between ASD and control groups for all participants in one 
version of the Systemizing Picture Task (n = 8) on the coin slide. Participants with ASD showed a gaze preference for 
the most systemized image. Relative duration was calculated from the sum of individual fixation times relative to the 
total fixation time for that slide. B. Participants with ASD showed a linear trend of increase in the fixation time with 
increasing levels of picture systemizing. This trend was absent in the control group. The interaction effect was not 
significant. The y-axis represents log-transformed proportion variable. The statistical significance of the linear trend of 
increase is noted: NS, not significant; * p < .05  
Figure 3. Visual systemizing preferences as a function of drug treatment and level of picture systemizing in ASD (A) 
versus control (CTL) (B) groups. Oxytocin significantly reversed the overall patterns of fixation time observed under 
placebo. A. Oxytocin (OT) compared with placebo (PL) significantly reduced the tendency for participants with ASD to 
fixate on the most systemized stimuli, while increasing their fixation on the least systemized stimuli, with marginal 
significance. After oxytocin, participants with ASD did not demonstrate a significant gaze preference. B. In the control 
group, oxytocin produced a significant preference to view more highly systemized pictures. The y-axis represents log-
transformed proportion variables. The statistical significance of the linear trend of increase or differences between 
oxytocin and placebo at specific levels of systemizing is noted: NS, not significant; † p < .1; * p < .05; ** p < .01; *** p 
< .001 
Figure 4. A. Contrasting effect of intranasal oxytocin on visual systemizing preference, based on the slope of fixation 
time vs. systemizing, in ASD vs. control participants.  Oxytocin decreased the systemizing preference in ASD 
participants, but increased systemizing preference in control participants. B. Model of how oxytocin levels may be 
associated with systemizing and empathizing characteristics in ASD and typically developing individuals. Effects of 
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systemizing are based on results displayed in (A). We propose that intranasal oxytocin may increase oxytocin levels in 
ASD participants from the low to normal range, while shifting the level in typically developing participants from 
normal to a high range. An inverted pattern may represent the effect of oxytocin on empathizing abilities, based on other 
studies of intranasal oxytocin in ASD and typically developing populations (see text). 
